Here's a look at a leader in HIV/AIDS treatments and a pioneering play in molecular diagnosis.
To overcome patent expirations, Bristol-Myers Squibb is pursing acquisitions.
U.S. clearance is a major milestone, but Bydureon faces stiff competition from its fast-selling rival.
This speculative biotech is a leading player in the race to commercialize genome sequencing.
Positive action on new drugs by FDA in 2011 bodes well for biopharmaceuticals in 2012, and Celgene can offer long-term growth.
Leadership changes at one of the world's largest and most underappreciated biotechs bode well for investors.
The acquisition is a vote of confidence in Isis Pharmaceuticals' drug development technology.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.